Assessing the effect of Yamanikadi Choornam and Agnimanth Kwatha with Shilajatu in the management of Non-alcoholic fatty liver disease(Yakritodara).

A comparative clinical study of Yamanikadi Choornam and Agnimanth Kwatha with Shilajatu in the management of Non-alcoholic fatty liver disease (Grade-I and Grade-II) w.s.r to Yakritodara-An Open Labelled Randomized Study. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/01/100266

Enrollment

Registered

2026-01-02

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age group between 20 to 60 Year (irrespective of gender, religion, economic status and race). 2.Patients with grade I and grade II Non-alcoholic fatty liver disease as per USG findings.

Exclusion criteria

Exclusion criteria: 1.Patients having History of uncontrolled HTN (more than160/100mmHg), DM type 1 and type 2. 2.BMI above 39.9 kg per m2 3.Diagnosed cases of alcoholic fatty liver disease, Hepatitis B and C, Cirrhosis of Liver. Pregnant and lactating women. 4.Patients with any communicable disease like TB, HIV etc. and diagnosed cases of comorbidities. 5.Any other clinical condition which may compromise the safety of the individual study participant.

Design outcomes

Primary

Measure	Time frame
Changes in the Ultrasonography (USG) findings.Timepoint: At initial visit and after completion of study.	—

Secondary

Measure	Time frame
To assess the effect of trial drugs on Liver function tests Parameters and Lipid profile.Timepoint: At initial visit and after completion of study.;To assess the changes in the clinical features of Non-alcoholic fatty liver disease (Grade-I and Grade-II) w.s.r to Yakritodara Timepoint: At initial visit and after completion of study.;Change in the score of Chronic Liver Disease Questionnarie (CLDQ-NASH Instrument).Timepoint: At initial visit, mid of the study(day 45) and after completion of study.;Incidence of adverse eventsTimepoint: During the study;Change in laboratory safety parameters (CBC, LFT, KFT)Timepoint: At initial visit and after completion of study.	—

Measure

Time frame

To assess the effect of trial drugs on Liver function tests Parameters and Lipid profile.Timepoint: At initial visit and after completion of study.;To assess the changes in the clinical features of Non-alcoholic fatty liver disease (Grade-I and Grade-II) w.s.r to Yakritodara Timepoint: At initial visit and after completion of study.;Change in the score of Chronic Liver Disease Questionnarie (CLDQ-NASH Instrument).Timepoint: At initial visit, mid of the study(day 45) and after completion of study.;Incidence of adverse eventsTimepoint: During the study;Change in laboratory safety parameters (CBC, LFT, KFT)Timepoint: At initial visit and after completion of study.

—

Countries

India

Contacts

Public ContactDr Sujata Yadav

Ayurvedic and Unani Tibbia College and Hospital,Karol Bagh,New Delhi 110005

sujatakcdelhi@gmail.com9810571653

Outcome results